BACKGROUND: RET proto-oncogene mutations are associated with medullary thyroid carcinomas usually requiring preventive thyroidectomy in gene carriers. We present a large kindred with the Y791F mutation in the RET proto-oncogene that did not have medullary thyroid carcinomas. PATIENTS AND METHODS: Eight members of a Danish family with the Y791F mutation participated. All gene carriers underwent pentagastrin testing, and measurements of serum calcitonin. In the index person, exons 10, 11, and 13-16 of the RET proto-oncogene were screened. In the rest of the individuals only exon 13 was analysed. Mutation analysis was done by direct bidirectional sequencing of PCR products on an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). RESULTS: The index person was screened genetically due to goitre at a young age. A total of 27 members of the family underwent genetic testing. Twelve (44.4%, 95% CI: 25.5%-64.7%) had the mutation (age range 13-84 years). None of these had abnormal pentagastrin tests (0%, 95% CI: 0%-26.5%). We found no significant differences in basal serum calcitonin concentrations between gene carriers (mean +/- SD: 0.16 +/- 0.54 pmol/l, n = 11) and non-gene carriers (0.55 +/- 0.86 pmol/l, n = 6, 2 P = 0.29). None showed signs of primary hyperparathyroidism or phaeochromocytoma. CONCLUSIONS: The Y791F RET proto-oncogene mutation may have a low penetrance. In selected cases, prophylactic thyroidectomy may be replaced by watchful waiting with repeated pentagastrin testing, provided careful evaluation of risks and benefits is performed.
BACKGROUND:RET proto-oncogene mutations are associated with medullary thyroid carcinomas usually requiring preventive thyroidectomy in gene carriers. We present a large kindred with the Y791F mutation in the RET proto-oncogene that did not have medullary thyroid carcinomas. PATIENTS AND METHODS: Eight members of a Danish family with the Y791F mutation participated. All gene carriers underwent pentagastrin testing, and measurements of serum calcitonin. In the index person, exons 10, 11, and 13-16 of the RET proto-oncogene were screened. In the rest of the individuals only exon 13 was analysed. Mutation analysis was done by direct bidirectional sequencing of PCR products on an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). RESULTS: The index person was screened genetically due to goitre at a young age. A total of 27 members of the family underwent genetic testing. Twelve (44.4%, 95% CI: 25.5%-64.7%) had the mutation (age range 13-84 years). None of these had abnormal pentagastrin tests (0%, 95% CI: 0%-26.5%). We found no significant differences in basal serum calcitonin concentrations between gene carriers (mean +/- SD: 0.16 +/- 0.54 pmol/l, n = 11) and non-gene carriers (0.55 +/- 0.86 pmol/l, n = 6, 2 P = 0.29). None showed signs of primary hyperparathyroidism or phaeochromocytoma. CONCLUSIONS: The Y791FRET proto-oncogene mutation may have a low penetrance. In selected cases, prophylactic thyroidectomy may be replaced by watchful waiting with repeated pentagastrin testing, provided careful evaluation of risks and benefits is performed.
Authors: Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert Journal: Ann Surg Date: 2002-11 Impact factor: 12.969
Authors: Linwah Yip; Gilbert J Cote; Suzanne E Shapiro; Gregory D Ayers; Cynthia E Herzog; Rena V Sellin; Steven I Sherman; Robert F Gagel; Jeffrey E Lee; Douglas B Evans Journal: Arch Surg Date: 2003-04
Authors: A Pasini; O Geneste; P Legrand; M Schlumberger; M Rossel; L Fournier; B B Rudkin; I Schuffenecker; G M Lenoir; M Billaud Journal: Oncogene Date: 1997-07-24 Impact factor: 9.867
Authors: Volker F H Brauer; Gerhard H Scholz; Susanne Neumann; Tobias Lohmann; Ralf Paschke; Christian A Koch Journal: Endocr Pract Date: 2004 Jan-Feb Impact factor: 3.443
Authors: Oliver Gimm; Barbara E Niederle; Theresa Weber; Maximilian Bockhorn; Jörg Ukkat; Michael Brauckhoff; Phuong Nguyen Thanh; Andreja Frilling; Ernst Klar; Bruno Niederle; Henning Dralle Journal: Surgery Date: 2002-12 Impact factor: 3.982
Authors: S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley Journal: Ann Surg Date: 1994-09 Impact factor: 12.969
Authors: Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs Journal: Thyroid Date: 2014-06-06 Impact factor: 6.568
Authors: Rodrigo A Toledo; Roxanne Hatakana; Delmar M Lourenço; Susan C Lindsey; Cleber P Camacho; Marcio Almeida; José V Lima; Tomoko Sekiya; Elena Garralda; Michel S Naslavsky; Guilherme L Yamamoto; Monize Lazar; Osorio Meirelles; Tiago J P Sobreira; Maria Lucia Lebrao; Yeda A O Duarte; John Blangero; Mayana Zatz; Janete M Cerutti; Rui M B Maciel; Sergio P A Toledo Journal: Endocr Relat Cancer Date: 2014-11-25 Impact factor: 5.678
Authors: Giovanni Innella; Cesare Rossi; Maria Romagnoli; Andrea Repaci; Davide Bianchi; Maria Elena Cantarini; Davide Martorana; Lea Godino; Andrea Pession; Antonio Percesepe; Uberto Pagotto; Daniela Turchetti Journal: Cancers (Basel) Date: 2020-11-05 Impact factor: 6.639